ID: MRFR/HC/7028-HCR | February 2021 | Region: Global | 115 pages
Systemic Lupus Erythematosus Treatment Market is expected to cross USD 1.5 Billion by 2025 at a CAGR of 6%.
Systemic lupus erythematosus is a disease that causes inflammation in connective tissues, like the lining of blood vessels and cartilage. Systemic lupus erythematosus medication includes nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarials, and corticosteroids amongst others. Early Systemic lupus erythematosus diagnosis and treatment can help to reduce the adverse effects of SLE and improve the chances of having a better life. SLE treatment currently includes administering drugs from four categories, namely corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarials, and Immunosuppressive agents and immune modulators.
Research and development for the launch of drugs, by key players, for the treatment of systemic lupus erythematosus.
By Route of Administration
By Distribution Channel
Frequently Asked Questions (FAQ) :
systemic lupus erythematosus treatment market is projected grow at approximately 6% CAGR during the assessment period (2019-2025).
The valuation of the global systemic lupus erythematosus treatment market is estimated to increase to USD 1.5 BN by the end of 2025.
The Immunosuppressive agents & immune modulators segment by treatment type holds the majority shares in the global systemic lupus erythematosus treatment market.
North America holds the largest share in the global systemic lupus erythematosus treatment market, followed by Europe and the Asia Pacific, respectively.
F. Hoffmann-La Roche Ltd (Switzerland), Sanofi (France), Novartis AG (Switzerland), GlaxoSmithKline plc (UK), Pfizer Inc. (US), AstraZeneca (UK), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Amgen Inc. (US), Johnson & Johnson Services, Inc. (US), and Anthera (US), are some of the major players operating in the global systemic lupus erythematosus treatment market.
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.